Home Regulatory Updates

Regulatory Updates

Daiichi Sankyo

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for HER2...

In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to...

Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab Govitecan for the...

Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved...